Which pharmaceutical companies are expected to announce new drug pricing deals with the Trump administration, and what is the context of these agreements?

Bayer (BAYGn.DE), Takeda (4502.T), CSL (CSL.AX), and several mid-size biotechs are expected to announce drug-pricing deals as part of the Trump administration’s push to lower prescription drug costs for Americans. These agreements build on prior deals with 17 major drugmakers—including Pfizer, Eli Lilly, and Amgen—under which companies agreed to offer lower prices comparable to those in other developed countries ('most-favored-nation' pricing), cut some prices for federal health programs, and sell medicines directly to patients via a Trump-branded website in exchange for tariff relief.

Why have smaller and mid-sized drugmakers been slower to join the Trump administration's drug pricing initiative, and what challenges does this pose?

Smaller and mid-sized drugmakers have delayed signing onto the drug pricing deals because, as reported by Reuters, many see little financial benefit—only Japan’s Astellas had confirmed applying for the Medicaid pricing program by June, and executives at firms like Ionis Pharmaceuticals stated they perceived minimal advantage. This slow uptake highlights a challenge for the administration’s broader affordability agenda, especially since the savings impact of the deals remains unclear, given that Medicaid already receives steep statutory discounts and most enrollees pay little out of pocket for prescriptions.

Trump Administration to Announce Drug Pricing Deals

Aug 31, 2026

The Trump administration plans to announce new drug-pricing agreements with major pharmaceutical firms like Bayer and Takeda, aiming to lower costs to match international levels. These deals could save $64.3 billion in federal spending over the next decade.

reuters

2026-08-31

Trump Administration to Announce Drug Pricing Deals

Trump Administration to Announce Drug Pricing Deals

FAQ